Loading
PRPS1 (Ribose-phosphate pyrophosphokinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute lymphoblastic leukaemia.
Catalyses the synthesis of phosphoribosylpyrophosphate (PRPP) that is essential for nucleotide synthesis.
CIViC holds 45 clinical evidence items and 0 assertions across 21 variants, naming Mercaptopurine, Thioguanine, Daunorubicin and Cytarabine and others.
In plain words · PRPS1 (Ribose-phosphate pyrophosphokinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute lymphoblastic leukaemia.
PRPS1 (Ribose-phosphate pyrophosphokinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute lymphoblastic leukaemia.
Catalyses the synthesis of phosphoribosylpyrophosphate (PRPP) that is essential for nucleotide synthesis. Locus Xq22.3 (HGNC).
No product in this corpus aims at PRPS1 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA PRPS1: RNA low tissue specificity; no normal tissue stained high; highest cancer staining cervical cancer (1 of 11 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Leukaemia); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas PRPS1 tissue; Open Targets ENSG00000147224 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Roessler B.J. et al, Nucleic Acids Res, 1990, "Cloning of two distinct copies of human phosphoribosylpyrophosphate synthetase cDNA". Source.
Sources: HGNC HGNC:9462 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P60891 (protein name, function text, keywords and locations (REST API)); CIViC gene PRPS1 (45 evidence items, 0 assertions, 21 variants; diseases: B-lymphoblastic Leukaemia/lymphoma (GraphQL API, CC0))
Catalyses the synthesis of phosphoribosylpyrophosphate (PRPP) that is essential for nucleotide synthesis. Locus Xq22.3 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
Medium only: breast cancer, colorectal cancer, endometrial cancer, liver cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PRPS1" OR ABSTRACT:"PRPS1" OR TITLE:"phosphoribosyl pyrophosphate synthetase 1" OR ABSTRACT:"phosphoribosyl pyrophosphate synthetase 1" OR TITLE:"Ribose-phosphate pyrophosphokinase 1" OR ABSTRACT:"Ribose-phosphate pyrophosphokinase 1" OR TITLE:"CMTX5" OR ABSTRACT:"CMTX5" OR TITLE:"DFNX1" OR ABSTRACT:"DFNX1" OR TITLE:"PRS-I" OR ABSTRACT:"PRS-I") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRPS1, not a curated reading list.